FDA Gives Priority Review to Tovorafenib in Pediatric Low-Grade Glioma

The FDA has granted priority review to a new drug application (NDA) for single-agent tovorafenib (DAY101) as a treatment for those with relapsed or progressive pediatric, low-grade glioma, according to a press release from Day One Biopharmaceuticals.

Read more: https://www.cancernetwork.com/view/fda-gives-priority-review-to-tovorafenib-in-pediatric-low-grade-glioma